Brief: Lianbio Announces China National Medical Products Administration (NMPA) Acceptance With Priority Review Of New Drug Application For Mavacamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy
21/04/2023 13:01
April 21 (Reuters) - LianBio LIAN.O :
* LIANBIO ANNOUNCES CHINA NATIONAL MEDICAL PRODUCTS
ADMINISTRATION
(NMPA) ACCEPTANCE WITH PRIORITY REVIEW OF NEW DRUG APPLICATION
FOR MAVACAMTEN FOR THE TREATMENT OF PATIENTS WITH OBSTRUCTIVE
HYPERTROPHIC CARDIOMYOPATHY
Source text for Eikon: ID:nGNX1Z83VY
Further company coverage: LIAN.O
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review